<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">37038497</PMID><DateRevised><Year>2024</Year><Month>09</Month><Day>16</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">2632-1297</ISSN><JournalIssue CitedMedium="Internet"><Volume>5</Volume><Issue>2</Issue><PubDate><Year>2023</Year></PubDate></JournalIssue><Title>Brain communications</Title><ISOAbbreviation>Brain Commun</ISOAbbreviation></Journal><ArticleTitle>Absence of self-reported neuropsychiatric and somatic symptoms after Omicron variant SARS-CoV-2 breakthrough infections.</ArticleTitle><Pagination><StartPage>fcad092</StartPage><MedlinePgn>fcad092</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">fcad092</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1093/braincomms/fcad092</ELocationID><Abstract><AbstractText>Persistent somatic and neuropsychiatric symptoms have been frequently described in patients after infection with severe acute respiratory syndrome coronavirus 2 even after a benign clinical course of the acute infection during the early phases of the coronavirus severe acute respiratory syndrome coronavirus 2 pandemic and are part of Long COVID. The Omicron variant emerged in November 2021 and has rapidly become predominant due to its high infectivity and suboptimal vaccine cross-protection. The frequency of neuropsychiatric post-acute sequelae after infection with the severe acute respiratory syndrome coronavirus 2 Omicron and adequate vaccination status is not known. Here, we aimed to characterize post-acute symptoms in individuals with asymptomatic or mildly symptomatic breakthrough infection with severe acute respiratory syndrome coronavirus 2. These individuals had either proven infection with the Omicron variant (<i>n</i> = 157) or their infection occurred in 2022 where Omicron was the predominant variant of severe acute respiratory syndrome coronavirus 2 in Germany (<i>n</i> = 107). This monocentric cross-sectional study was conducted at the University Medical Center Hamburg-Eppendorf between 11 February 2022 and 11 April 2022. We employed questionnaires addressing self-reported somatic symptom burden (Somatic Symptom Scale 8) and neuropsychiatric symptoms including mood (Patient Health Questionnaire 2), anxiety (Generalized Anxiety Disorder 7), attention (Mindful Attention Awareness Scale) and fatigue (Fatigue Assessment Scale) in a cohort of hospital workers. Scores were compared between 175 individuals less than 4 weeks after positive testing for severe acute respiratory syndrome coronavirus 2, 88 individuals more than 4 weeks after positive testing and 87 severe acute respiratory syndrome coronavirus 2 uninfected controls. The majority (<i>n</i> = 313; 89.5%) of included individuals were vaccinated at least three times. After recovery from infection, no significant differences in scores assessing neuropsychiatric and somatic symptoms were detected between the three groups (severe acute respiratory syndrome coronavirus 2 uninfected controls, individuals less and more than 4 weeks after positive testing) independent of age, sex, preconditions and vaccination status. In addition, self-reported symptom burden did not significantly correlate with the number of vaccinations against severe acute respiratory syndrome coronavirus 2, time from recovery or the number of infections. Notably, in all three groups, the mean scores for each item of our questionnaire lay below the pathological threshold. Our data show that persistent neuropsychiatric and somatic symptoms after recovery from severe acute respiratory syndrome coronavirus 2 infection in fully vaccinated hospital workers do not occur more frequently than that in uninfected individuals. This will guide healthcare professionals in the clinical management of patients after recovery from breakthrough infections with severe acute respiratory syndrome coronavirus 2.</AbstractText><CopyrightInformation>&#xa9; The Author(s) 2023. Published by Oxford University Press on behalf of the Guarantors of Brain.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Woo</LastName><ForeName>Marcel S</ForeName><Initials>MS</Initials><Identifier Source="ORCID">0000-0002-1306-2708</Identifier><AffiliationInfo><Affiliation>Institute of Neuroimmunology and Multiple Sclerosis, University Medical Center Hamburg-Eppendorf, Hamburg 20251, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mayer</LastName><ForeName>Christina</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Institute of Neuroimmunology and Multiple Sclerosis, University Medical Center Hamburg-Eppendorf, Hamburg 20251, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brehm</LastName><ForeName>Thomas Theo</ForeName><Initials>TT</Initials><AffiliationInfo><Affiliation>German Center for Infection Research (DZIF), Partner Site Hamburg-L&#xfc;beck-Borstel-Riems, Hamburg 20246, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>I. Department of Medicine, University Medical Center Hamburg-Eppendorf, Hamburg 20246, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Andersen</LastName><ForeName>Gabriele</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Occupational Safety and Health, University Medical Center Hamburg-Eppendorf, Hamburg 20246, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Weigel</LastName><ForeName>Angelika</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Psychosomatic Medicine and Psychotherapy, University Medical Center Hamburg-Eppendorf, Hamburg 20246, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>L&#xf6;we</LastName><ForeName>Bernd</ForeName><Initials>B</Initials><Identifier Source="ORCID">0000-0003-4220-3378</Identifier><AffiliationInfo><Affiliation>Department of Psychosomatic Medicine and Psychotherapy, University Medical Center Hamburg-Eppendorf, Hamburg 20246, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lohse</LastName><ForeName>Ansgar W</ForeName><Initials>AW</Initials><AffiliationInfo><Affiliation>German Center for Infection Research (DZIF), Partner Site Hamburg-L&#xfc;beck-Borstel-Riems, Hamburg 20246, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>I. Department of Medicine, University Medical Center Hamburg-Eppendorf, Hamburg 20246, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Addo</LastName><ForeName>Marylyn M</ForeName><Initials>MM</Initials><AffiliationInfo><Affiliation>German Center for Infection Research (DZIF), Partner Site Hamburg-L&#xfc;beck-Borstel-Riems, Hamburg 20246, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>I. Department of Medicine, University Medical Center Hamburg-Eppendorf, Hamburg 20246, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute for Infection Research and Vaccine Development, University Medical Center Hamburg-Eppendorf, Hamburg 20246, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gerloff</LastName><ForeName>Christian</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Neurology, University Medical Center Hamburg-Eppendorf, Hamburg 20251, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Knobloch</LastName><ForeName>Johannes K M</ForeName><Initials>JKM</Initials><Identifier Source="ORCID">0000-0002-2591-6387</Identifier><AffiliationInfo><Affiliation>German Center for Infection Research (DZIF), Partner Site Hamburg-L&#xfc;beck-Borstel-Riems, Hamburg 20246, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Medical Microbiology, Virology and Hygiene, Department for Infection Prevention and Control, University Medical Center Hamburg-Eppendorf, Hamburg 20246, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schulze Zur Wiesch</LastName><ForeName>Julian</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0002-5033-1938</Identifier><AffiliationInfo><Affiliation>German Center for Infection Research (DZIF), Partner Site Hamburg-L&#xfc;beck-Borstel-Riems, Hamburg 20246, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>I. Department of Medicine, University Medical Center Hamburg-Eppendorf, Hamburg 20246, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Friese</LastName><ForeName>Manuel A</ForeName><Initials>MA</Initials><Identifier Source="ORCID">0000-0001-6380-2420</Identifier><AffiliationInfo><Affiliation>Institute of Neuroimmunology and Multiple Sclerosis, University Medical Center Hamburg-Eppendorf, Hamburg 20251, Germany.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>03</Month><Day>25</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Brain Commun</MedlineTA><NlmUniqueID>101755125</NlmUniqueID><ISSNLinking>2632-1297</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Long COVID</Keyword><Keyword MajorTopicYN="N">Omicron</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2 breakthrough infection</Keyword><Keyword MajorTopicYN="N">neuropsychiatric deficits</Keyword></KeywordList><CoiStatement>The authors declare no competing interests and no conflict of interest. MAF received honoraria for consultation and travel expenses from Biogen, Merck KGaA, Novartis and Roche unrelated to this work.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>7</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>11</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>3</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>4</Month><Day>12</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>4</Month><Day>11</Day><Hour>1</Hour><Minute>46</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>4</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>3</Month><Day>25</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37038497</ArticleId><ArticleId IdType="pmc">PMC10082557</ArticleId><ArticleId IdType="doi">10.1093/braincomms/fcad092</ArticleId><ArticleId IdType="pii">fcad092</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>von Felden J, Brehm TT, Schulze zur Wiesch J, et al. . Erratum zu: Milde COVID-19-Verl&#xe4;ufe bei Mitarbeitenden einer Universit&#xe4;tsklinik. Bundesgesundheitsblatt - Gesundheitsforsch - Gesundheitsschutz. 2022;65(3):398&#x2013;398.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8443902</ArticleId><ArticleId IdType="pubmed">34529097</ArticleId></ArticleIdList></Reference><Reference><Citation>Petersen EL, Go&#xdf;ling A, Adam G, et al. . Multi-organ assessment in mainly non-hospitalized individuals after SARS-CoV-2 infection: The Hamburg City Health Study COVID programme. Eur Heart J. 2022;43(11):1124&#x2013;1137.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8755397</ArticleId><ArticleId IdType="pubmed">34999762</ArticleId></ArticleIdList></Reference><Reference><Citation>Hampshire A, Trender W, Chamberlain SR, et al. . Cognitive deficits in people who have recovered from COVID-19. EClinicalMedicine. 2021;39:101044.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8298139</ArticleId><ArticleId IdType="pubmed">34316551</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Aly Z, Xie Y, Bowe B. High-dimensional characterization of post-acute sequelae of COVID-19. Nature. 2021;594(7862):259&#x2013;264.</Citation><ArticleIdList><ArticleId IdType="pubmed">33887749</ArticleId></ArticleIdList></Reference><Reference><Citation>Sudre CH, Murray B, Varsavsky T, et al. . Attributes and predictors of Long COVID. Nat Med. 2021;27(4):626&#x2013;631.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7611399</ArticleId><ArticleId IdType="pubmed">33692530</ArticleId></ArticleIdList></Reference><Reference><Citation>Sivan M, Taylor S. NICE guideline on Long COVID. BMJ. 2020;371:m4938.</Citation><ArticleIdList><ArticleId IdType="pubmed">33361141</ArticleId></ArticleIdList></Reference><Reference><Citation>Crook H, Raza S, Nowell J, Young M, Edison P. Long COVID&#x2014;Mechanisms, risk factors, and management. BMJ. 2021;374:n1648.</Citation><ArticleIdList><ArticleId IdType="pubmed">34312178</ArticleId></ArticleIdList></Reference><Reference><Citation>Davis HE, Assaf GS, McCorkell L, et al. . Characterizing Long COVID in an international cohort: 7 months of symptoms and their impact. EClinicalMedicine. 2021;38:101019.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8280690</ArticleId><ArticleId IdType="pubmed">34308300</ArticleId></ArticleIdList></Reference><Reference><Citation>Logue JK, Franko NM, McCulloch DJ, et al. . Sequelae in adults at 6 months after COVID-19 infection. JAMA Netw Open. 2021;4(2):e210830.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7896197</ArticleId><ArticleId IdType="pubmed">33606031</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang EY, Mao T, Klein J, et al. . Diverse functional autoantibodies in patients with COVID-19. Nature. 2021;595(7866):283&#x2013;288.</Citation><ArticleIdList><ArticleId IdType="pubmed">34010947</ArticleId></ArticleIdList></Reference><Reference><Citation>Rojas M, Rodr&#xed;guez Y, Acosta-Ampudia Y, et al. . Autoimmunity is a hallmark of post-COVID syndrome. J Transl Med. 2022;20(1):129.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8924736</ArticleId><ArticleId IdType="pubmed">35296346</ArticleId></ArticleIdList></Reference><Reference><Citation>Su Y, Yuan D, Chen DG, et al. . Multiple early factors anticipate post-acute COVID-19 sequelae. Cell. 2022;185(5):881&#x2013;895.e20.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8786632</ArticleId><ArticleId IdType="pubmed">35216672</ArticleId></ArticleIdList></Reference><Reference><Citation>Moriguchi T, Harii N, Goto J, et al. . A first case of meningitis/encephalitis associated with SARS-coronavirus-2. Int J Infect Dis. 2020;94:55&#x2013;58.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7195378</ArticleId><ArticleId IdType="pubmed">32251791</ArticleId></ArticleIdList></Reference><Reference><Citation>Oxley TJ, Mocco J, Majidi S, et al. . Large-Vessel stroke as a presenting feature of COVID-19 in the young. N Engl J Med. 2020;382(20):e60.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7207073</ArticleId><ArticleId IdType="pubmed">32343504</ArticleId></ArticleIdList></Reference><Reference><Citation>Nalleballe K, Reddy Onteddu S, Sharma R, et al. . Spectrum of neuropsychiatric manifestations in COVID-19. Brain Behav Immun. 2020;88:71&#x2013;74 .</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7297688</ArticleId><ArticleId IdType="pubmed">32561222</ArticleId></ArticleIdList></Reference><Reference><Citation>Rogers JP, Chesney E, Oliver D, et al. . Psychiatric and neuropsychiatric presentations associated with severe coronavirus infections: A systematic review and meta-analysis with comparison to the COVID-19 pandemic. Lancet Psychiatry. 2020;7(7):611&#x2013;627.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7234781</ArticleId><ArticleId IdType="pubmed">32437679</ArticleId></ArticleIdList></Reference><Reference><Citation>Varatharaj A, Thomas N, Ellul MA, et al. . Neurological and neuropsychiatric complications of COVID-19 in 153 patients: A UK-wide surveillance study. Lancet Psychiatry. 2020;7(10):875&#x2013;882.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7316461</ArticleId><ArticleId IdType="pubmed">32593341</ArticleId></ArticleIdList></Reference><Reference><Citation>Woo MS, Malsy J, P&#xf6;ttgen J, et al. . Frequent neurocognitive deficits after recovery from mild COVID-19. Brain Commun. 2020;2(2):fcaa205.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7717144</ArticleId><ArticleId IdType="pubmed">33376990</ArticleId></ArticleIdList></Reference><Reference><Citation>Fern&#xe1;ndez-Casta&#xf1;eda A, Lu P, Geraghty AC, et al. . Mild respiratory COVID can cause multi-lineage neural cell and myelin dysregulation. Cell. 2022;185:2452&#x2013;2468.e16 .</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9189143</ArticleId><ArticleId IdType="pubmed">35768006</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Aly Z, Bowe B, Xie Y. Long COVID after breakthrough SARS-CoV-2 infection. Nat Med. 2022;28:1461&#x2013;1467.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9307472</ArticleId><ArticleId IdType="pubmed">35614233</ArticleId></ArticleIdList></Reference><Reference><Citation>Juthani PV, Gupta A, Borges KA, et al. . Hospitalisation among vaccine breakthrough COVID-19 infections. Lancet Infect Dis. 2021;21(11):1485&#x2013;1486.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8423430</ArticleId><ArticleId IdType="pubmed">34506735</ArticleId></ArticleIdList></Reference><Reference><Citation>Sormani MP, Schiavetti I, Inglese M, et al. . Breakthrough SARS-CoV-2 infections after COVID-19 mRNA vaccination in MS patients on disease modifying therapies during the Delta and the Omicron waves in Italy. eBioMedicine. 2022;80:104042.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9069178</ArticleId><ArticleId IdType="pubmed">35526306</ArticleId></ArticleIdList></Reference><Reference><Citation>Coburn SB, Humes E, Lang R, et al. . Analysis of postvaccination breakthrough COVID-19 infections among adults with HIV in the United States. JAMA Netw Open. 2022;5(6):e2215934.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9175076</ArticleId><ArticleId IdType="pubmed">35671054</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang L, Wang Q, Davis PB, Volkow ND, Xu R. Increased risk for COVID-19 breakthrough infection in fully vaccinated patients with substance use disorders in the United States between December 2020 and August 2021. World Psychiatry. 2022;21(1):124&#x2013;132.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8661963</ArticleId><ArticleId IdType="pubmed">34612005</ArticleId></ArticleIdList></Reference><Reference><Citation>Brehm TT, Thompson M, Ullrich F, et al. . Low SARS-CoV-2 infection rates and high vaccine-induced immunity among German healthcare workers at the end of the third wave of the COVID-19 pandemic. Int J Hyg Environ Health. 2021;238:113851.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8463331</ArticleId><ArticleId IdType="pubmed">34601375</ArticleId></ArticleIdList></Reference><Reference><Citation>De Vries J. Assessment of fatigue among working people: A comparison of six questionnaires. Occup Environ Med. 2003; 60(Suppl 1):10i&#x2013;115.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1765720</ArticleId><ArticleId IdType="pubmed">12782741</ArticleId></ArticleIdList></Reference><Reference><Citation>Horisberger A, Courvoisier D, Ribi C. The Fatigue Assessment Scale as a simple and reliable tool in systemic lupus erythematosus: A cross-sectional study. Arthritis Res Ther. 2019;21(1):80.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6434822</ArticleId><ArticleId IdType="pubmed">30909957</ArticleId></ArticleIdList></Reference><Reference><Citation>Michielsen HJ, De Vries J, Van Heck GL. Psychometric qualities of a brief self-rated fatigue measure. J Psychosom Res. 2003;54(4):345&#x2013;352.</Citation><ArticleIdList><ArticleId IdType="pubmed">12670612</ArticleId></ArticleIdList></Reference><Reference><Citation>Carlson LE, Brown KW. Validation of the Mindful Attention Awareness Scale in a cancer population. J Psychosom Res. 2005;58(1):29&#x2013;33.</Citation><ArticleIdList><ArticleId IdType="pubmed">15771867</ArticleId></ArticleIdList></Reference><Reference><Citation>Brown KW, Ryan RM. The benefits of being present: Mindfulness and its role in psychological well-being. J Pers Soc Psychol. 2003;84(4):822&#x2013;848.</Citation><ArticleIdList><ArticleId IdType="pubmed">12703651</ArticleId></ArticleIdList></Reference><Reference><Citation>Kroenke K, Spitzer RL, Williams JBW, Lowe B. An ultra-brief screening scale for anxiety and depression: The PHQ-4. Psychosomatics. 2009;50(6):613&#x2013;621.</Citation><ArticleIdList><ArticleId IdType="pubmed">19996233</ArticleId></ArticleIdList></Reference><Reference><Citation>Spitzer RL, Kroenke K, Williams JBW, L&#xf6;we B. A brief measure for assessing Generalized Anxiety Disorder. Arch Intern Med. 2006;166(10):1092.</Citation><ArticleIdList><ArticleId IdType="pubmed">16717171</ArticleId></ArticleIdList></Reference><Reference><Citation>Kroenke K, Spitzer RL, Williams JBW, Monahan PO, L&#xf6;we B. Anxiety disorders in primary care: Prevalence, impairment, comorbidity, and detection. Ann Intern Med. 2007;146(5):317.</Citation><ArticleIdList><ArticleId IdType="pubmed">17339617</ArticleId></ArticleIdList></Reference><Reference><Citation>Gierk B, Kohlmann S, Kroenke K, et al. . The Somatic Symptom Scale&#x2013;8 (SSS-8). JAMA Intern Med. 2014;174(3):399.</Citation><ArticleIdList><ArticleId IdType="pubmed">24276929</ArticleId></ArticleIdList></Reference><Reference><Citation>Kortela E, Kirjavainen V, Ahava MJ, et al. . Real-life clinical sensitivity of SARS-CoV-2 RT-PCR test in symptomatic patients. Ricci S, ed. PLoS One. 2021;16(5):e0251661.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8139477</ArticleId><ArticleId IdType="pubmed">34019562</ArticleId></ArticleIdList></Reference><Reference><Citation>Nagura-Ikeda M, Imai K, Tabata S, et al. . Clinical evaluation of self-collected Saliva by quantitative reverse transcription-PCR (RT-qPCR), direct RT-qPCR, reverse transcription&#x2013;loop-mediated isothermal amplification, and a rapid antigen test to diagnose COVID-19. J Clin Microbiol. 2020;58(9):e01438-20.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7448663</ArticleId><ArticleId IdType="pubmed">32636214</ArticleId></ArticleIdList></Reference><Reference><Citation>Pfefferle S, Reucher S, N&#xf6;rz D, L&#xfc;tgehetmann M. Evaluation of a quantitative RT-PCR assay for the detection of the emerging coronavirus SARS-CoV-2 using a high throughput system. Eurosurveillance. 2020;25(9):2000152.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7068162</ArticleId><ArticleId IdType="pubmed">32156329</ArticleId></ArticleIdList></Reference><Reference><Citation>Townsend L, Dyer AH, Jones K, et al. . Persistent fatigue following SARS-CoV-2 infection is common and independent of severity of initial infection. Madeddu G, ed. PLoS One. 2020;15(11):e0240784.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7652254</ArticleId><ArticleId IdType="pubmed">33166287</ArticleId></ArticleIdList></Reference><Reference><Citation>Nasserie T, Hittle M, Goodman SN. Assessment of the frequency and variety of persistent symptoms among patients with COVID-19. JAMA Netw Open. 2021;4(5):e2111417.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8155823</ArticleId><ArticleId IdType="pubmed">34037731</ArticleId></ArticleIdList></Reference><Reference><Citation>Groff D, Sun A, Ssentongo AE, et al. . Short-term and long-term rates of postacute sequelae of SARS-CoV-2 infection. JAMA Netw Open. 2021;4(10):e2128568.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8515212</ArticleId><ArticleId IdType="pubmed">34643720</ArticleId></ArticleIdList></Reference><Reference><Citation>Petersen M, N&#xe4;gele FL, Mayer C, et al. . Brain imaging and neuropsychological assessment of individuals recovered from mild to moderate SARS-CoV-2 infection. medRxiv. 2022.doi:10.1101/2022.07.08.22277420</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2022.07.08.22277420</ArticleId><ArticleId IdType="pmc">PMC10235949</ArticleId><ArticleId IdType="pubmed">37220275</ArticleId></ArticleIdList></Reference><Reference><Citation>Quandt J, Muik A, Salisch N, et al. . 1 Breakthrough infection drives cross-variant neutralization and memory B cell formation against conserved epitopes. Sci Immunol. 2022;7:eabq2427.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9162083</ArticleId><ArticleId IdType="pubmed">35653438</ArticleId></ArticleIdList></Reference><Reference><Citation>Larkin HD. Four vaccine doses prevented severe Omicron COVID-19 better than 3. JAMA. 2022;327(18):1748.</Citation><ArticleIdList><ArticleId IdType="pubmed">35536278</ArticleId></ArticleIdList></Reference><Reference><Citation>Antonelli M, Pujol JC, Spector TD, Ourselin S, Steves CJ. Risk of Long COVID associated with delta versus Omicron variants of SARS-CoV-2. Lancet. 2022;399(10343):2263&#x2013;2264.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9212672</ArticleId><ArticleId IdType="pubmed">35717982</ArticleId></ArticleIdList></Reference><Reference><Citation>Woo MS, Haag F, Nierhaus A, et al. . Multi-dimensional and longitudinal systems profiling reveals predictive pattern of severe COVID-19. iScience. 2021;24(7):102752.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8213514</ArticleId><ArticleId IdType="pubmed">34179733</ArticleId></ArticleIdList></Reference><Reference><Citation>Solomon IH, Normandin E, Bhattacharyya S, et al. . Neuropathological features of COVID-19. N Engl J Med. 2020;383:989&#x2013;992 .</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7304421</ArticleId><ArticleId IdType="pubmed">32530583</ArticleId></ArticleIdList></Reference><Reference><Citation>Matschke J, L&#xfc;tgehetmann M, Hagel C, et al. . Neuropathology of patients with COVID-19 in Germany: A post-mortem case series. Lancet Neurol. 2020;19(11):919&#x2013;929.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7535629</ArticleId><ArticleId IdType="pubmed">33031735</ArticleId></ArticleIdList></Reference><Reference><Citation>Krasemann S, Haferkamp U, Pfefferle S, et al. . The blood-brain barrier is dysregulated in COVID-19 and serves as a CNS entry route for SARS-CoV-2. Stem Cell Reports. 2022;11(2):578&#x2013;592.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8772030</ArticleId><ArticleId IdType="pubmed">35063125</ArticleId></ArticleIdList></Reference><Reference><Citation>Varga Z, Flammer AJ, Steiger P, et al. . Endothelial cell infection and endotheliitis in COVID-19. Lancet. 2020;395(10234):1417&#x2013;1418.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7172722</ArticleId><ArticleId IdType="pubmed">32325026</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang AC, Kern F, Losada PM, et al. . Dysregulation of brain and choroid plexus cell types in severe COVID-19. Nature. 2021;595(7868):565&#x2013;571.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8400927</ArticleId><ArticleId IdType="pubmed">34153974</ArticleId></ArticleIdList></Reference><Reference><Citation>Rutkai I, Mayer MG, Hellmers LM, et al. . Neuropathology and virus in brain of SARS-CoV-2 infected non-human primates. Nat Commun. 2022;13(1):1745.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8975902</ArticleId><ArticleId IdType="pubmed">35365631</ArticleId></ArticleIdList></Reference><Reference><Citation>Leppkes M, Knopf J, Naschberger E, et al. . Vascular occlusion by neutrophil extracellular traps in COVID-19. EBioMedicine. 2020;58:102925.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7397705</ArticleId><ArticleId IdType="pubmed">32745993</ArticleId></ArticleIdList></Reference><Reference><Citation>Phetsouphanh C, Darley DR, Wilson DB, et al. . Immunological dysfunction persists for 8 months following initial mild-to-moderate SARS-CoV-2 infection. Nat Immunol. 2022;23(2):210&#x2013;216.</Citation><ArticleIdList><ArticleId IdType="pubmed">35027728</ArticleId></ArticleIdList></Reference><Reference><Citation>L&#xf6;we B, Andresen V, Van den Bergh O, et al. . Persistent SOMAtic symptoms ACROSS diseases&#x2014;From risk factors to modification: Scientific framework and overarching protocol of the interdisciplinary SOMACROSS research unit (RU 5211). BMJ Open. 2022;12(1):e057596.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8785206</ArticleId><ArticleId IdType="pubmed">35063961</ArticleId></ArticleIdList></Reference><Reference><Citation>Matta J, Wiernik E, Robineau O, et al. . Association of self-reported COVID-19 infection and SARS-CoV-2 serology test results with persistent physical symptoms among French adults during the COVID-19 pandemic. JAMA Intern Med. 2022;182(1):19.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8576624</ArticleId><ArticleId IdType="pubmed">34747982</ArticleId></ArticleIdList></Reference><Reference><Citation>Taquet M, Dercon Q, Harrison PJ. Six-month sequelae of post-vaccination SARS-CoV-2 infection: A retrospective cohort study of 10,024 breakthrough infections. Brain Behav Immun. 2022;103:154&#x2013;162.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9013695</ArticleId><ArticleId IdType="pubmed">35447302</ArticleId></ArticleIdList></Reference><Reference><Citation>Hachmann NP, Miller J, Collier AY, et al. . Neutralization Escape by SARS-CoV-2 Omicron subvariants BA.2.12.1, BA.4, and BA.5. N Engl J Med. 2022;387(1):86&#x2013;88.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9258748</ArticleId><ArticleId IdType="pubmed">35731894</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>